Business Wire

CGTN: Tibetan Religious Leader Extends Wishes for Spring Festival, Tibetan New Year

12.2.2021 16:50:00 EET | Business Wire | Press release

Share

The Tibetan New Year falls on the same day as the Spring Festival this year. As a long, bitter winter starts petering down, colorful spring sneaks in.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210212005297/en/

Bainqen Erdini Qoigyijabu, the 11th Panchen Lama, on Friday expressed best wishes to all Tibetans at home and abroad for both the Spring Festival and the Tibetan Year of the Iron Ox through China Media Group (CMG) and China Tibet Online.

Looking back at the past year, he expressed his affirmation that China has overcome difficulties in the face of the pandemic. "The whole country united together, and all people worked with one heart, achieving outstanding results in preventing and controlling the COVID-19 pandemic, which draws much worldwide attention," he said.

"From the pandemic, we have further understood how precious life is. As I see it, health, peace and happiness are the most precious fortune in human life. From the pandemic, we have also further understood that all human beings are in a community with a shared future."

He also expressed his understanding of the importance of a community with a shared future for mankind.

Erdini Qoigyijabu spoke of the historic alleviation of poverty in Tibet and of people in the region living and working in peace and contentment, and expressed his sincere gratitude to the country. "I feel very gratified to see the new Tibet today," he said. "A glorious time and a happy homeland is not a gift from nature. We should remain grateful for our country, and for the thousands upon thousands of people willing to sacrifice for us.”

Finally, he offered New Year blessings to the people of the whole country. "Let us jointly wish and pray the world be peaceful, the country be prosperous, the people live in peace, the weather be favorable, and all living things live joyfully! I wish everyone and every family be happy, safe and sound in the New Year and reap a new harvest," he concluded.

The Tibetan New Year, known as Losar, is the most important festival on the Tibetan calendar.

Celebrating Losar, Tibetan New Year, on the plateau

Losar is roughly the same as the Spring Festival of the Han ethnic group.

The Tibetan New Year is calculated based on the Tibetan calendar. It starts on the first day of the first month of the Tibetan calendar and ends on the 15th day. It falls on February 12 this year.

Originally a harvest celebration, the festival gradually shifted to the beginning of a new year, after Princess Wencheng of the Tang Dynasty (618-907) married Songtsen Gampo, the then Tibetan King, and brought to the southwestern Chinese region the culture of the Han people.

For the Tibetans and those who have been exploring the Tibetan New Year on the plateau, Tashi delek, and Happy New Year!

A developing Tibet

Transportation has long been a bottleneck inhibiting Tibet's development, as the region is situated on the Qinghai-Tibet Plateau with complex geographical conditions for road construction and limited technology and funds.

Since late 2012, China has been bolstering its infrastructure investment in Tibet. So far, roads have connected 95 percent of the township-level administrations and 75 percent of the incorporated villages in the region. The road network in Tibet now stretches over 117,000 kilometers, up by 50 percent from the end of 2015.

As for air transportation, Tibet has launched a total of 130 air routes, with 61 cities connected by flights; 5.18 million passenger trips were registered in 2020.

The development of Tibet is well-founded with data.

With the strong support of the central government and the active assistance from the local people, the economy of Tibet has been developing steadily.

In 2018, Tibet registered a GDP growth rate of 10 percent, the highest in China.

According to the released work reports from the local governments in February 2021, Tibet led the 2020 growth rate among the country's 31 provincial-level regions, at 7.8 percent, followed by southwestern provinces of Guizhou and Yunnan, at 4.5 and 4 percent, respectively.

In 2021, Tibet's GDP growth target stands at over 9 percent, while the pace is set around 8 percent for Guizhou and Yunnan provinces.

Original article: here.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
Jiang Simin
jiang.simin@cgtn.com
+86 18826553286

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 14:30:00 EEST | Press release

Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye